BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19036682)

  • 1. [Role of FDG PET-CT in cutaneous melanoma].
    Nicol I; Chuto G; Gaudy-Marqueste C; Brenot-Rossi I; Grob JJ; Richard MA
    Bull Cancer; 2008 Nov; 95(11):1089-101. PubMed ID: 19036682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
    Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
    Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
    Clark PB; Soo V; Kraas J; Shen P; Levine EA
    Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma.
    Havenga K; Cobben DC; Oyen WJ; Nienhuijs S; Hoekstra HJ; Ruers TJ; Wobbes T
    Eur J Surg Oncol; 2003 Oct; 29(8):662-4. PubMed ID: 14511614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of lymph node ultrasound and whole body
    Stahlie EHA; van der Hiel B; Bruining A; van de Wiel B; Schrage YM; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Eur J Surg Oncol; 2021 May; 47(5):1157-1162. PubMed ID: 33353826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorodeoxyglucose-PET in the management of malignant melanoma.
    Kumar R; Mavi A; Bural G; Alavi A
    Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma.
    Bikhchandani J; Wood J; Richards AT; Smith RB
    Head Neck; 2014 Sep; 36(9):1313-6. PubMed ID: 23956077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma.
    Cheng D; McNicoll CF; Kirgan D; Jones MS; Rivera MR; Doyle GM; De Guzman MD; Baynosa J; St Hill CR
    Am J Surg; 2021 Apr; 221(4):737-740. PubMed ID: 32354604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study.
    Klein M; Freedman N; Lotem M; Marciano R; Moshe S; Gimon Z; Chisin R
    Nuklearmedizin; 2000; 39(3):56-61. PubMed ID: 10834191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET in early stage cutaneous malignant melanoma.
    McIvor J; Siew T; Campbell A; McCarthy M
    J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
    Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
    J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
    Kumar R; Alavi A
    Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
    Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
    J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma.
    Kurli M; Chin K; Finger PT
    Br J Ophthalmol; 2008 Apr; 92(4):479-82. PubMed ID: 18369064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.
    Maubec E; Lumbroso J; Masson F; Suciu V; Kolb F; Mamelle G; Cavalcanti A; Boitier F; Spatz A; Aupérin A; Leboulleux S; Avril MF
    Melanoma Res; 2007 Jun; 17(3):147-54. PubMed ID: 17505260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma.
    Bastiaannet E; Hoekstra HJ; Hoekstra OS
    Methods Mol Biol; 2011; 727():123-39. PubMed ID: 21331932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FDG-PET in the assessment of survival prognosis in melanoma.
    Pleiss C; Risse JH; Biersack HJ; Bender H
    Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.